VRTX250117P455000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Leerink Partners Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
Vertex Pharmaceuticals' Suzetrigine: A Promising Opioid Alternative in Pain Management
Vertex Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Earnings Preview: Vertex Pharmaceuticals (VRTX) Q4 Earnings Expected to Decline
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $533
Press Release: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Cuts Target Price to $450
Vertex Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $480
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
Vertex Pharmaceuticals (VRTX) Receives a Hold From RBC Capital
Antibody Drug Conjugates Market Size Is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research
RBC Adjusts Price Target on Vertex Pharmaceuticals to $402 From $401, Maintains Sector Perform Rating
Express News | Vertex Pharmaceuticals Inc : RBC Raises Target Price to $402 From $401
Erste Group Initiates Vertex Pharmaceuticals(VRTX.US) With Hold Rating
8 Health Care Stocks Whale Activity In Today's Session
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $522
Bank of America Securities Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?